Botulinum neurotoxin A (BoNT-A), often referred to as ‘Botox’, is increasingly in cosmetic procedures. However, long-term use and high doses of BoNT-A may lead to immunoresistance, limiting its future therapeutic benefit.

A panel of experts including Dr Mary Dingley, Cosmetic Medicine Centre, Australia, is addressing this emerging issue. They offer guidance to practitioners and promote a culture of open communication with patients about BoNT-A risks, to empower individuals to make a fully informed decision.

Read more in Research Outreach

Read their original article : https://www.doi.org/10.1097/GOX.0000000000004407